What Happened?
Newport Beach, CA-based jCyte Appointed Adam Walsh as Chief Financial Officer
About the Company
jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company`s allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.
About the Person
Adam Walsh is Chief Financial Officer at jCyte. Previously, Adam held various senior HR leadership roles in the industry.
Info Source
News
Short Profile